Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review

Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL(+) B‐ALL. Dasatinib is a potent second‐generation TKI. Here, we have discussed the case of a 51‐year‐old gentleman diagnosed with B‐myeloid mixed‐phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR–ABL1p210, in com...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Theresa, Ellahie, Anil Yousaf, Almohtasib, Yazan Salah, Sinha, Urshita, El Omri, Halima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175909/
https://www.ncbi.nlm.nih.gov/pubmed/35844702
http://dx.doi.org/10.1002/jha2.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175909/
https://www.ncbi.nlm.nih.gov/pubmed/35844702
http://dx.doi.org/10.1002/jha2.226

Ejemplares similares